BEIJING, China, May 01, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 34,085 vehicles in April 2026. As of April 30, 2026, Li Auto’s cumulative deliveries reached 1,669,442. In April, the all-new Li L9 Livis debuted at the 2026 Beijing International Automotive Exhibition,...
BEIJING, China, May 01, 2026 (GLOBE NEWSWIRE) -- Li Auto Inc. (“Li Auto” or the “Company”) (Nasdaq: LI; HKEX: 2015), a leader in China’s new energy vehicle market, today announced that it delivered 34,085 vehicles in April 2026. As of April 30, 2026, Li Auto’s cumulative deliveries reached 1,669,442. In April, the all-new Li L9 Livis debuted at the 2026 Beijing International Automotive Exhibition, with its official launch scheduled for May 15. The launch event will fully showcase the vehicle’s l
L3Harris' Missile Business Files To Go Public As Trump's War Economy Prepares For Launch We have been diligently tracking the Trump administration's war-economy mobilization across the homeland, from the rise of so-called " war unicorns " favored by the Department of War to Trump officials talking with GM, Ford, GE Aerospace, and Oshkosh about converting underused civilian industrial capacity into...
L3Harris' Missile Business Files To Go Public As Trump's War Economy Prepares For Launch We have been diligently tracking the Trump administration's war-economy mobilization across the homeland, from the rise of so-called " war unicorns " favored by the Department of War to Trump officials talking with GM, Ford, GE Aerospace, and Oshkosh about converting underused civilian industrial capacity into weapons production. The signal to investors is becoming hard to miss: the Trump administration is preparing to expand the defense industrial base at scale to refill depleted weapons stockpiles. Whether through venture-backed defense startups, legacy defense primes, or redirected auto and heavy-manufacturing capacity, the White House's war policies point toward a major weapons-production boom on the horizon. With that in mind, L3Harris Technologies has confidentially filed a draft S-1 with the SEC for a proposed IPO of its Missile Solutions business, or MSL. L3Harris is now preparing for an IPO, as the SEC privately reviews the draft registration statement and may send comments or request changes. This occurs before the IPO roadshow begins. Last week, L3Harris announced it had closed a $1 billion investment from the DoW into MSL, which will be used to "accelerate research and development, and increase production capacity for critical national security technologies." "This strategic partnership with the Department of War is a testament to the critical role L3Harris plays in our national security," L3Harris CEO Christopher Kubasik wrote in a statement. Kubasik noted, “The investment will allow us to accelerate innovation and enhance our ability to deliver the advanced capabilities our warfighters need to deter and defeat emerging threats. We are proud to partner with the DoW to ensure the resilience of our defense industrial base for years to come." Related: Race To Refill U.S. Weapons Stockpiles Will Supercharge War Economy War Economy Returns: From Trucks To Tanks, Pentagon...
Seaport Therapeutics Inc. , a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range. The neuro-psychiatry company sold 14.16 million shares at $18 each, according to a statement Thursday confirming an earlier Bloomberg News report. The biotech firm had offer...
Seaport Therapeutics Inc. , a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, raised nearly $255 million in an upsized US initial public offering that priced at the top of its marketed range. The neuro-psychiatry company sold 14.16 million shares at $18 each, according to a statement Thursday confirming an earlier Bloomberg News report. The biotech firm had offered 11.8 million shares for $16 to $18 each, its filings show. At the IPO price, the Boston-based firm has a market value of about $912 million based on the outstanding shares listed in the filings. The listing was significantly oversubscribed, people familiar with the matter said earlier. Biotechnology IPOs have picked up in recent weeks. The latest, blood coagulation disorder drugmaker Hemab Therapeutics Holdings Inc., raised $301.5 million in an upsized US initial public offering that priced earlier Thursday. Founded in 2024, the clinical-stage company is developing therapies to treat patients with major depressive disorder and generalized anxiety disorder. The company, which is backed by PureTech Health Plc , had a net loss of $74.9 million last year, compared with a net loss of $46.9 million a year earlier, according to the filings. Nasdaq and London Stock Exchange-listed PureTech’s stake is expected to decline to 33% after the offering from 43%, the filings show. Affiliates of Arch Ventures Partners will have a 10% stake, down from 13%, and General Atlantic is set to have 6.6%, down from 8.6%. For the latest news on equity capital markets activity in the US, Canada and Latin America, follow the channel or visit NI BFWECMUS . To subscribe to ECM Watch , Bloomberg’s daily roundup of news from around the region, click here . The offering is being led by Goldman Sachs Group Inc. , JPMorgan Chase & Co. , Leerink Partners , Citigroup Inc. and Stifel Financial Corp. The shares are expected to trade on the Nasdaq Global Market under the symbol SPTX.
Beijing urges Washington to ‘make the right choices’ on Taiwan to maintain ‘stability’ between the two powers China’s foreign minister on Thursday urged the US to maintain “stability” between the two powers and warned that Taiwan posed the biggest risk, weeks ahead of President Donald Trump’s scheduled visit to Beijing. In a call with the US secretary of state, Marco Rubio, foreign minister Wang Y...
Beijing urges Washington to ‘make the right choices’ on Taiwan to maintain ‘stability’ between the two powers China’s foreign minister on Thursday urged the US to maintain “stability” between the two powers and warned that Taiwan posed the biggest risk, weeks ahead of President Donald Trump’s scheduled visit to Beijing. In a call with the US secretary of state, Marco Rubio, foreign minister Wang Yi said that Beijing and Washington should “safeguard the hard-won stability” in China-US relations, China’s foreign ministry said. Continue reading...
marekuliasz/iStock Editorial via Getty Images I first covered Amprius Technologies, Inc. ( AMPX ), back in February. I liked the growth potential of the company and the market in which it operates. Battery technology demand is only growing. One of the things I liked is that their battery technology is utilized in some fast-growing markets, such as UAVs, and not just the car space. Their market opp...
marekuliasz/iStock Editorial via Getty Images I first covered Amprius Technologies, Inc. ( AMPX ), back in February. I liked the growth potential of the company and the market in which it operates. Battery technology demand is only growing. One of the things I liked is that their battery technology is utilized in some fast-growing markets, such as UAVs, and not just the car space. Their market opportunity is continuing to grow with eVTOLs, robotics, space, and other markets. The valuation was a little rich for me at the time of writing . I rated the stock a hold and would look for any pullbacks to enter a long position. At the time I covered the stock, it was trading in the mid-$11 a share; when it pulled back below $10 a share, I took a position in the stock. My only regret was not taking a larger position. Amprius has been on a tear to start the year. The company has seen its stock price increase by over 160% year to date. The company reported strong quarterly results, particularly on the margin side of the business. Current world events have also helped drive the stock. There is increased demand on the military side for drones. Also, many are seeing the reliance on oil and seeing alternative energy options as a solution. Amprius is well positioned to capitalize on growing demand. Seeking Alpha The company has seen strong growth as its products have fully entered the market. The performance of its products continues to drive demand in the market. Its new battery, SiCore, is fully implemented in the market and is much more profitable as well. The company has crossed over into the point of profitability as well, which is a big step for a small, growing company. This should help drive value for the company going forward. Similar to last time I reviewed the stock, I like the company and the industry in which it operates. I think the recent run-up has positioned the stock at a high valuation. Financials The company has seen strong growth as it has entered the full comm...
Earnings Call Insights: DexCom (DXCM) Q1 2026 Management view DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter revenue growth of 15% compared to the first quarter of 2025 and organic revenue growth of 12%,” and linking performance to “broader access, new product launches and co...
Earnings Call Insights: DexCom (DXCM) Q1 2026 Management view DexCom reported Q1 momentum tied to coverage expansion, product rollout, and operational execution, with President, CEO & Director Jacob Leach highlighting “first quarter revenue growth of 15% compared to the first quarter of 2025 and organic revenue growth of 12%,” and linking performance to “broader access, new product launches and continued active base growth.” Leach emphasized U.S. type 2 share gains, saying the “biggest increase” came from “people with type 2 diabetes who are not on insulin,” supported by “greater than 6 million non-insulin lives currently covered for Dexcom CGM across the 3 largest PBMs.” On incremental U.S. reimbursement, Leach announced, “As of this summer, Prime Therapeutics will begin covering DexCom CGM for all people with diabetes,” adding, “This puts us on track to have commercial coverage for more than 7 million type 2 non-insulin lives by the end of this year.” Product execution centered on G7 15 Day, with Leach describing “an outstanding launch of G7 15 Day” and adding the rollout “has been very well received,” with feedback “around the new sensor algorithm, which delivers our highest level of accuracy to date.” Leach flagged near-term product and software updates, saying DexCom “began manufacturing with our new patch technology,” and “expect this new technology to reach the market in the coming weeks,” alongside a “complete redesign of Stelo” featuring “more AI-driven personalized insights and additional food logging capabilities, including detailed macronutrient information.” Executive VP, CFO & Chief Accounting Officer Jereme Sylvain framed Q1 financial delivery and margin drivers, saying, “we reported worldwide revenue of $1.19 billion,” and gross margin was “63.5% of revenue,” reflecting “continued manufacturing efficiencies, more normalized freight costs… and initial benefit from the switch over to G7 15 Day.” Outlook Sylvain reiterated full-year revenue guidance: “W...
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the ...
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the public of $5.00 per share, and in lieu of common stock, to certain investors, pre-funded warrants to purchase 8,000,000 shares of common stock at a purchase price of $4.999 per pre-funded warrant share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $80 million. In addition, Senseonics granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 4, 2026, subject to satisfaction of customary closing conditions. The pre-funded warrants will not be listed on any securities exchange.
BlackRock is the unquestionable 800-lb. Gorilla of the asset management universe. At $14 trillion AUM, BlackRock’s total assets are greater than the combined GDP of Russia, Japan, UK and Germany, and roughly 67% of the entire GDP of China. As one might expect, BlackRock casts its shadow far and wide across the entire spectrum of ... iShares’ AI ETF Returned 91% Last Year. Can It Do It Again in 202...
BlackRock is the unquestionable 800-lb. Gorilla of the asset management universe. At $14 trillion AUM, BlackRock’s total assets are greater than the combined GDP of Russia, Japan, UK and Germany, and roughly 67% of the entire GDP of China. As one might expect, BlackRock casts its shadow far and wide across the entire spectrum of ... iShares’ AI ETF Returned 91% Last Year. Can It Do It Again in 2026?
Footage posted on social media by federal prosecutors includes captions claiming Cole Tomas Allen shot first Federal prosecutors released footage Thursday of the moment officials say Cole Tomas Allen tried to storm last week’s White House Correspondents’ Association ’s dinner in an alleged attempt to kill Donald Trump . Amid questions about whether or not Allen fired his weapon before being subdue...
Footage posted on social media by federal prosecutors includes captions claiming Cole Tomas Allen shot first Federal prosecutors released footage Thursday of the moment officials say Cole Tomas Allen tried to storm last week’s White House Correspondents’ Association ’s dinner in an alleged attempt to kill Donald Trump . Amid questions about whether or not Allen fired his weapon before being subdued, Jeanine Pirro, the top federal prosecutor in Washington DC, released edited security camera footage of the incident in a social media post . Continue reading...